Loading...
Loading...
Browse all stories on DeepNewz
VisitHow will Axsome's stock price react within a week of FDA decision on AXS-05?
Increase by 10% or more • 25%
Decrease by 10% or more • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Stock market data from a reliable financial platform like Bloomberg or Yahoo Finance
Axsome Therapeutics Plans FDA NDA Submission for AXS-05 in Alzheimer’s Disease in 2H 2025 After Phase 3 Trials Show p=0.001
Dec 30, 2024, 12:40 PM
Axsome Therapeutics has announced plans to submit a New Drug Application (NDA) to the FDA for its Alzheimer’s disease treatment, AXS-05, in the second half of 2025. This decision follows the completion of a Phase 3 clinical program, which reportedly achieved its primary endpoint compared to placebo, with a p-value of 0.001 for time to relapse. However, the results from the ADVANCE-2 trial did not demonstrate statistical significance, although there were numerically greater improvements with AXS-05 over placebo in both primary and secondary endpoints. The mixed results from these trials have raised questions about the approvability of the data package by the FDA, but Axsome remains optimistic about moving forward.
View original story
Increase by less than 10% • 25%
Increase by over 10% • 25%
Decrease by over 10% • 25%
Decrease by less than 10% • 25%
Increase 0-20% • 25%
No change • 25%
Decrease • 25%
Increase over 20% • 25%
Decrease • 25%
No significant change • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Outperforms biotech index • 25%
Underperforms biotech index • 25%
No significant change • 25%
Performs in line with biotech index • 25%
Decrease by more than 5% • 25%
Change within +/- 5% • 25%
Increase by more than 5% • 25%
Other • 25%
Yes • 50%
No • 50%
Increase by 0-20% • 25%
Decrease by more than 20% • 25%
Decrease by 0-20% • 25%
Increase by more than 20% • 25%
Decrease by over 10% • 25%
Decrease by 0-10% • 25%
Increase by 0-10% • 25%
Increase by over 10% • 25%
Rejection • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Increase over 10% • 25%
Other • 25%
No significant change • 25%
Decrease over 10% • 25%
10% to 20% • 25%
Less than 5% • 25%
More than 20% • 25%
5% to 10% • 25%